GNH USA

Europe — EMA

Miflonide Breezhaler (Budesonide)

GNH USA supplies Miflonide Breezhaler (Budesonide), an inhaled corticosteroid for asthma and COPD.

Budesonide

Request sourcing

1
Pack/s

What is Budesonide?

Budesonide, the active ingredient in Miflonide Breezhaler, is an inhaled corticosteroid presented as an inhalation powder for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) in adults and children as prescribed.

GNH USA supplies Miflonide Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Budesonide used for?

Miflonide Breezhaler, containing budesonide, is used in the management of inflammatory airway diseases.

- Asthma: improves symptom control and reduces the frequency of exacerbations. - COPD: decreases breathlessness and lowers the risk of flare‑ups. - Chronic bronchial inflammation: provides maintenance therapy to lessen airway swelling and improve lung function.

What are the side effects of Budesonide?

Common Side Effects: - Oral candidiasis (thrush): fungal infection in the mouth. - Hoarseness or dysphonia: voice changes. - Throat irritation or cough. - Headache.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced endogenous cortisol production. - Severe allergic reaction: anaphylaxis or angioedema.

What precautions apply to Budesonide?

Before using Miflonide Breezhaler, consider the following precautions: - Assess infection risk: monitor for respiratory infections. - Monitor growth in children: schedule regular pediatric assessments. - Avoid abrupt discontinuation: taper the dose if used long‑term. - Use mouth rinse after inhalation: reduces risk of oral candidiasis. - Pregnancy Category B: prescribe only when benefit outweighs potential risk. - Store at ambient temperature: keep in original container, protect from moisture and heat.

What does Budesonide interact with?

Budesonide may interact with other medicines. Review the following:

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic exposure. - Live vaccines: risk of reduced vaccine efficacy due to immunosuppression. - Systemic corticosteroids: additive immunosuppressive effects.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalemia risk. - Beta‑agonists: may mask bronchospasm symptoms.

Frequently asked questions

What is Miflonide Breezhaler used for?+
Miflonide Breezhaler contains budesonide, an inhaled corticosteroid that is prescribed to manage chronic inflammatory airway conditions such as asthma and chronic obstructive pulmonary disease (COPD). It helps reduce airway swelling, mucus production, and improves breathing over the long term.
How does budesonide work in the lungs?+
Budesonide binds to glucocorticoid receptors in the cells lining the airways, altering gene expression to suppress inflammatory mediators, eosinophil activity, and mast cell degranulation. This reduces airway inflammation, edema, and hyper‑responsiveness, leading to better airflow and fewer symptoms.
What is the usual dose of Miflonide Breezhaler?+
The dose of Miflonide Breezhaler is individualized by the prescribing healthcare professional based on the severity of the disease, patient age, and response to therapy. Patients should follow the exact regimen written on their prescription and consult their clinician for any adjustments.
Is Miflonide Breezhaler safe during pregnancy or breastfeeding?+
Budesonide is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data suggest minimal transfer into breast milk, but a clinician should evaluate the risk‑benefit ratio for nursing mothers.
How do I order Miflonide Breezhaler from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.
How does Miflonide Breezhaler compare with other inhaled corticosteroids?+
Miflonide Breezhaler delivers budesonide via a dry‑powder Breezhaler device, offering consistent dose delivery and rapid onset. Compared with other inhaled corticosteroids such as fluticasone or beclomethasone, budesonide has a slightly lower systemic bioavailability, which may reduce the risk of systemic side effects while providing comparable efficacy in controlling asthma and COPD.
What are the storage and handling requirements for Miflonide Breezhaler?+
Store Miflonide Breezhaler at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and excessive heat. Keep the device away from direct sunlight and do not expose it to freezing conditions. Ensure the inhaler is kept out of reach of children.
How is Miflonide Breezhaler administered?+
The patient inhales the powdered medication through the Breezhaler device by placing the mouthpiece in the mouth, sealing lips around it, and inhaling sharply and deeply. After each dose, the device should be closed and stored as instructed. Patients are advised to rinse their mouth with water and spit out the rinse to reduce oral side effects.
What are the most serious risks associated with Miflonide Breezhaler?+
Serious risks, though rare, include paradoxical bronchospasm (a sudden worsening of breathing), adrenal suppression leading to reduced cortisol production, and severe allergic reactions such as anaphylaxis or angioedema. Patients should seek immediate medical attention if they experience sudden breathlessness, severe swelling, or signs of an allergic reaction.
Who should not use Miflonide Breezhaler?+
Miflonide Breezhaler should not be used by individuals with a known hypersensitivity to budesonide, other inhaled corticosteroids, or any component of the formulation. It is also contraindicated in patients who have experienced a severe paradoxical bronchospasm after using an inhaled corticosteroid. Clinicians should evaluate each patient’s medical history before prescribing.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Budesonide
Route
Inhalation Use
Manufacturer
Novartis Farma S.P.A.
Origin
EU

Related products

Budesonide .25 mg/2mL

Budesonide .25 mg/2mL

Budesonide · 0.25 mg/2 mL

Budesonide
SUSPENSION
Teva Pharmaceuticals USA, Inc.
USA
Budesonide .25 mg/2mL

Budesonide .25 mg/2mL

Budesonide · 0.25 mg/2 mL

Budesonide
SUSPENSION
Teva Pharmaceuticals USA, Inc.
USA
Budesonide .25 mg/2mL

Budesonide .25 mg/2mL

Budesonide · 0.25 mg/2 mL

Budesonide
SUSPENSION
Teva Pharmaceuticals USA, Inc.
USA
Budesonide .5 mg/2mL

Budesonide .5 mg/2mL

Budesonide · 0.5 mg/2 mL

Budesonide
SUSPENSION
Teva Pharmaceuticals USA, Inc.
USA